US 12,152,082 B2
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
Denise L. Faustman, Boston, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US)
Filed on Jan. 15, 2021, as Appl. No. 17/150,686.
Application 17/150,686 is a continuation of application No. 15/573,747, granted, now 10,906,982, previously published as PCT/US2016/032547, filed on May 13, 2016.
Claims priority of provisional application 62/276,073, filed on Jan. 7, 2016.
Claims priority of provisional application 62/162,449, filed on May 15, 2015.
Prior Publication US 2021/0317221 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/395 (2013.01); A61K 38/00 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating a cancer in a human with the cancer, said method comprising administering to the human an antagonistic antibody or antigen-binding fragment thereof capable of specifically binding human TNFR2, wherein the antibody or antigen-binding fragment thereof comprises the following CDRs:
(a) a CDR-H1 having the amino acid sequence GYTFTDYX (SEQ ID NO: 257);
(b) a CDR-H2 having the amino acid sequence VDPEYGST (SEQ ID NO: 258);
(c) a CDR-H3 having the amino acid sequence ARDDGSYSPFDYWG (SEQ ID NO: 259);
(d) a CDR-L1 having the amino acid sequence QNINKY (SEQ ID NO: 260);
(e) a CDR-L2 having the amino acid sequence TYS or YTS; and
(f) a CDR-L3 having the amino acid sequence CLQYVNLXT (SEQ ID NO: 261);
wherein each X is independently a leucine or isoleucine, wherein the antibody or antigen-binding fragment thereof inhibits T regulatory (Treg) cell proliferation in the presence of TNFα, and wherein said antibody or antigen-binding fragment thereof comprises a non-native constant region.